| Literature DB >> 26348784 |
Hélène C Bertrand1, Marjolein Schaap1, Liam Baird2, Nikolaos D Georgakopoulos1, Adrian Fowkes1, Clarisse Thiollier1, Hiroko Kachi1, Albena T Dinkova-Kostova2,3, Geoff Wells1.
Abstract
The transcription factor Nrf2 regulates the expression of a large network of cytoprotective and metabolic enzymes and proteins. Compounds that directly and reversibly inhibit the interaction between Nrf2 and its main negative regulator Keap1 are potential pharmacological agents for a range of disease types including neurodegenerative conditions and cancer. We describe the development of a series of 1,4-diphenyl-1,2,3-triazole compounds that inhibit the Nrf2-Keap1 protein-protein interaction (PPI) in vitro and in live cells and up-regulate the expression of Nrf2-dependent gene products.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26348784 DOI: 10.1021/acs.jmedchem.5b00602
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446